Total Payments
$408.88
2023 Payments
$207.97
Companies
11
Transactions
27
Medicare Patients
2,849
Medicare Billing
$182,948
Payment Breakdown by Category
Food & Beverage$408.88 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $408.88 | 27 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB, Inc. | $186.43 | 13 | $0 (2023) |
| GlaxoSmithKline, LLC. | $65.13 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $30.67 | 2 | $0 (2021) |
| Neurocrine Biosciences, Inc. | $25.34 | 1 | $0 (2022) |
| Alkermes, Inc. | $16.98 | 1 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $16.72 | 1 | $0 (2019) |
| Lilly USA, LLC | $15.76 | 1 | $0 (2021) |
| PFIZER INC. | $15.26 | 1 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $13.58 | 1 | $0 (2018) |
| Purdue Pharma L.P. | $11.87 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $207.97 | 14 | UCB, Inc. ($168.76) |
| 2022 | $54.27 | 3 | Neurocrine Biosciences, Inc. ($25.34) |
| 2021 | $75.66 | 5 | Novartis Pharmaceuticals Corporation ($30.67) |
| 2020 | $17.67 | 1 | UCB, Inc. ($17.67) |
| 2019 | $16.72 | 1 | Sunovion Pharmaceuticals Inc. ($16.72) |
| 2018 | $24.72 | 2 | Janssen Pharmaceuticals, Inc ($13.58) |
| 2017 | $11.87 | 1 | Purdue Pharma L.P. ($11.87) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY, SHINGRIX | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: RESPIRATORY | ||||||
| 11/17/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Neurology | ||||||
| 11/17/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $4.11 | General |
| Category: Neurology | ||||||
| 11/17/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $3.49 | General |
| Category: Neurology | ||||||
| 08/30/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $27.42 | General |
| Category: Neurology | ||||||
| 08/30/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $4.30 | General |
| Category: Neurology | ||||||
| 06/17/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Neurology | ||||||
| 05/19/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $32.51 | General |
| Category: Neurology | ||||||
| 05/19/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $1.23 | General |
| Category: Neurology | ||||||
| 04/28/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: Neurology | ||||||
| 04/28/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $9.51 | General |
| Category: Neurology | ||||||
| 04/28/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $2.11 | General |
| Category: Neurology | ||||||
| 04/14/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $36.32 | General |
| Category: Neurology | ||||||
| 03/29/2023 | PFIZER INC. | PREMARIN (Drug), ESTRING, MYFEMBREE | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: WOMENS HEALTH | ||||||
| 11/30/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: Neuropsychiatry | ||||||
| 02/09/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA INITIO | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: CNS | ||||||
| 01/18/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $11.95 | General |
| Category: RESPIRATORY | ||||||
| 06/07/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: RESPIRATORY | ||||||
| 04/07/2021 | GlaxoSmithKline, LLC. | BEXSERO (Biological), PEDIARIX | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: VACCINES | ||||||
| 04/06/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/03/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $11.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/19/2021 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Diabetes | ||||||
| 10/08/2020 | UCB, Inc. | Neupro (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Neurology | ||||||
| 08/22/2019 | Sunovion Pharmaceuticals Inc. | Aptiom (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: CNS | ||||||
| 08/09/2018 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $11.14 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 241 | 523 | $11,072 | $3,416 |
| 2022 | 10 | 634 | 1,183 | $64,807 | $32,213 |
| 2021 | 19 | 1,117 | 1,984 | $139,563 | $81,546 |
| 2020 | 21 | 857 | 1,327 | $110,817 | $65,774 |
Total Patients
2,849
Total Services
5,017
Medicare Billing
$182,948
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 83036 | Hemoglobin a1c level | Office | 2023 | 80 | 130 | $4,011 | $1,222 | 30.5% |
| 82947 | Blood glucose (sugar) level | Office | 2023 | 105 | 315 | $4,703 | $1,220 | 25.9% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 11 | 14 | $700.00 | $484.68 | 69.2% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 11 | 22 | $550.00 | $343.43 | 62.4% |
| 81002 | Urinalysis, manual test | Office | 2023 | 23 | 30 | $728.00 | $101.83 | 14.0% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2023 | 11 | 12 | $380.01 | $44.01 | 11.6% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2022 | 162 | 192 | $28,800 | $14,357 | 49.9% |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | Office | 2022 | 40 | 196 | $11,800 | $6,851 | 58.1% |
| 87502 | Detection test by nucleic acid for multiple types influenza virus | Office | 2022 | 42 | 42 | $5,425 | $4,005 | 73.8% |
| 82947 | Blood glucose (sugar) level | Office | 2022 | 135 | 435 | $6,488 | $1,686 | 26.0% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 115 | 174 | $5,375 | $1,669 | 31.1% |
| 87486 | Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | Office | 2022 | 42 | 42 | $2,478 | $1,467 | 59.2% |
| 87581 | Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique | Office | 2022 | 40 | 40 | $2,360 | $1,398 | 59.3% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 18 | 18 | $900.00 | $630.27 | 70.0% |
| 81002 | Urinalysis, manual test | Office | 2022 | 25 | 29 | $725.00 | $99.80 | 13.8% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2022 | 15 | 15 | $456.00 | $48.12 | 10.6% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2021 | 222 | 279 | $41,850 | $20,925 | 50.0% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 81 | 114 | $18,962 | $15,663 | 82.6% |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | Office | 2021 | 62 | 336 | $19,883 | $11,790 | 59.3% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 84 | 119 | $11,781 | $7,395 | 62.8% |
| 87502 | Detection test by nucleic acid for multiple types influenza virus | Office | 2021 | 53 | 59 | $7,525 | $5,652 | 75.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 32 | 32 | $4,352 | $4,043 | 92.9% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Office | 2021 | 31 | 31 | $3,565 | $2,548 | 71.5% |
| 87486 | Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | Office | 2021 | 59 | 65 | $3,835 | $2,281 | 59.5% |
| 87581 | Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique | Office | 2021 | 59 | 65 | $3,835 | $2,281 | 59.5% |
About Muhammad Ata
Muhammad Ata is a Internal Medicine healthcare provider based in Pisgah, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023112307.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Muhammad Ata has received a total of $408.88 in payments from pharmaceutical and medical device companies, with $207.97 received in 2023. These payments were reported across 27 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($408.88).
As a Medicare-enrolled provider, Ata has provided services to 2,849 Medicare beneficiaries, totaling 5,017 services with total Medicare billing of $182,948. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Pisgah, AL
- Active Since 09/08/2006
- Last Updated 02/23/2009
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023112307
Products in Payments
- Briviact (Drug) $168.76
- TRELEGY ELLIPTA (Drug) $52.80
- ENTRESTO (Drug) $30.67
- INGREZZA (Drug) $25.34
- Neupro (Drug) $17.67
- ARISTADA (Drug) $16.98
- Aptiom (Drug) $16.72
- TRULICITY (Drug) $15.76
- PREMARIN (Drug) $15.26
- XARELTO (Drug) $13.58
- BEXSERO (Biological) $12.33
- OXYCONTIN (Drug) $11.87
- Tresiba (Drug) $11.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.